Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Colgate-Palmolive Company (CL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Colgate-Palmolive Company — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Colgate-Palmolive Company trades at $92.91 (market cap $73.81B). The key difference: Colgate-Palmolive Company is the larger of the two by market cap, and Colgate-Palmolive Company pays a 2.3% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CL | |
|---|---|---|
Market Cap | $39.89B | $73.81B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $99.14 |
52-Week Low | $278.09 | $74.98 |
Enterprise Value | $38.15B | $80.45B |
Dividend Yield | — | 2.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Colgate-Palmolive (CL) trades at $92.24, up 1.35% on the day, reflecting strong momentum with a bullish technical signal and consistent earnings beats. The company maintains robust profitability with a 60.06% gross margin and 10.04% net income margin, though its P/E of 35.75 and P/B of 509.03 indicate premium valuation. Recent news highlights its status as a Dividend King with a 64-year streak, supported by stable cash flow from operations of $4.20B in 2025.
Outlook remains positive with analyst consensus target of $95.56, but risks include North American segment softness and inflationary pressures. The stock offers income stability through dividends, yet high valuation multiples may limit near-term upside absent accelerated growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →
